NASDAQ:ZVRA Zevra Therapeutics (ZVRA) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free ZVRA Stock Alerts $4.50 -0.06 (-1.32%) (As of 03:26 PM ET) Add Compare Share Share Today's Range$4.48▼$4.5550-Day Range$4.50▼$7.0852-Week Range$3.89▼$7.28Volume73,017 shsAverage Volume249,788 shsMarket Capitalization$195.44 millionP/E RatioN/ADividend YieldN/APrice Target$19.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Zevra Therapeutics alerts: Email Address Zevra Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside332.4% Upside$19.50 Price TargetShort InterestBearish5.93% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.78Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.65) to ($0.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.55 out of 5 starsMedical Sector665th out of 907 stocksPharmaceutical Preparations Industry301st out of 422 stocks 3.5 Analyst's Opinion Consensus RatingZevra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZevra Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.93% of the float of Zevra Therapeutics has been sold short.Short Interest Ratio / Days to CoverZevra Therapeutics has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Zevra Therapeutics has recently increased by 5.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldZevra Therapeutics does not currently pay a dividend.Dividend GrowthZevra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZVRA. Previous Next 3.8 News and Social Media Coverage News SentimentZevra Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Zevra Therapeutics this week, compared to 2 articles on an average week.Search Interest10 people have searched for ZVRA on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.MarketBeat Follows6 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zevra Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Zevra Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 35.03% of the stock of Zevra Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zevra Therapeutics are expected to grow in the coming year, from ($1.65) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zevra Therapeutics is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zevra Therapeutics is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZevra Therapeutics has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Zevra Therapeutics Stock (NASDAQ:ZVRA)Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.Read More ZVRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZVRA Stock News HeadlinesApril 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAApril 20, 2024 | americanbankingnews.comDaré Bioscience (NASDAQ:DARE) vs. Zevra Therapeutics (NASDAQ:ZVRA) Head-To-Head ContrastApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 18, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Boosted by AnalystApril 15, 2024 | globenewswire.comZevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual MeetingApril 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAApril 10, 2024 | globenewswire.comZevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit FacilityApril 10, 2024 | globenewswire.comZevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit FacilityApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 4, 2024 | finance.yahoo.comZevra Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAApril 3, 2024 | markets.businessinsider.comZevra Therapeutics: Poised for Transformation and Growth Amidst Market OverreactionApril 3, 2024 | finance.yahoo.comBearish: Analysts Just Cut Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Revenue and EPS estimatesApril 2, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAApril 1, 2024 | insidermonkey.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call TranscriptMarch 31, 2024 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported, And Analysts Assigned A US$18.25 Price TargetMarch 30, 2024 | seekingalpha.comZevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | investorplace.comZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023March 28, 2024 | benzinga.comZevra Therapeutics: Q4 Earnings InsightsMarch 28, 2024 | globenewswire.comZevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesMarch 27, 2024 | benzinga.comEarnings Outlook For Zevra TherapeuticsMarch 26, 2024 | globenewswire.comZevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic HypersomniaMarch 25, 2024 | globenewswire.comZevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 19, 2024 | finance.yahoo.comKemPharm Inc (1GDA.DU)March 18, 2024 | globenewswire.comZevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024March 14, 2024 | finance.yahoo.comZevra Therapeutics (NASDAQ:ZVRA) investors are sitting on a loss of 81% if they invested five years agoMarch 4, 2024 | markets.businessinsider.comZevra Therapeutics Says FDA Extends NDA Review Period For ArimoclomolSee More Headlines Receive ZVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ZVRA CUSIPN/A CIK1434647 Webwww.kempharm.com Phone(321) 939-3416Fax319-665-2577Employees32Year FoundedN/APrice Target and Rating Average Stock Price Target$19.50 High Stock Price Target$25.00 Low Stock Price Target$15.00 Potential Upside/Downside+332.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,050,000.00 Net Margins-167.69% Pretax Margin-167.69% Return on Equity-68.41% Return on Assets-35.19% Debt Debt-to-Equity Ratio0.08 Current Ratio1.18 Quick Ratio1.18 Sales & Book Value Annual Sales$27.46 million Price / Sales7.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.71 per share Price / Book2.64Miscellaneous Outstanding Shares43,430,000Free Float42,384,000Market Cap$195.87 million OptionableOptionable Beta1.81 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. R. LaDuane Clifton CPA (Age 52)CFO, Secretary, Treasurer & Director Comp: $563.22kMr. Neil F. McFarlane (Age 51)President, CEO & Director Ms. Christal M. M. Mickle M.A. (Age 45)Co-Founder & Chief Development Officer Dr. Sven Guenther Ph.D. (Age 52)Chief Scientific Officer Comp: $497.26kMs. Nichol L. OchsnerVice President of Investor Relations & Corporate CommunicationsDr. Christopher M. Lauderback Ph.D. (Age 49)Senior Vice President of Manufacturing Dr. Rene A. Braeckman Ph.D.Senior Vice President of Clinical DevelopmentMr. Joshua M. Schafer M.B.A. (Age 52)Chief Commercial Officer, Executive VP of Business Development & Director Dr. Daniel Gallo Ph.D.Senior Vice President of Medical Affairs & AdvocacyDr. Adrian Quartel FFPM (Age 56)M.D., Chief Medical Officer More ExecutivesKey CompetitorsRigel PharmaceuticalsNASDAQ:RIGLOrganigramNASDAQ:OGITrevi TherapeuticsNASDAQ:TRVILifecore BiomedicalNASDAQ:LFCRDesign TherapeuticsNASDAQ:DSGNView All CompetitorsInsiders & InstitutionsIFG Advisors LLCBought 5,800 shares on 4/25/2024Ownership: 0.043%Virtu Financial LLCBought 26,966 shares on 2/26/2024Ownership: 0.074%Armistice Capital LLCBought 268,000 shares on 2/13/2024Ownership: 0.740%Tower Research Capital LLC TRCBought 5,545 shares on 2/13/2024Ownership: 0.027%Focus Financial Network Inc. ADVBought 21,500 shares on 2/12/2024Ownership: 0.059%View All Insider TransactionsView All Institutional Transactions ZVRA Stock Analysis - Frequently Asked Questions Should I buy or sell Zevra Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zevra Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZVRA shares. View ZVRA analyst ratings or view top-rated stocks. What is Zevra Therapeutics' stock price target for 2024? 6 Wall Street analysts have issued twelve-month target prices for Zevra Therapeutics' stock. Their ZVRA share price targets range from $15.00 to $25.00. On average, they anticipate the company's stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 332.4% from the stock's current price. View analysts price targets for ZVRA or view top-rated stocks among Wall Street analysts. How have ZVRA shares performed in 2024? Zevra Therapeutics' stock was trading at $6.55 at the start of the year. Since then, ZVRA shares have decreased by 31.1% and is now trading at $4.51. View the best growth stocks for 2024 here. When is Zevra Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ZVRA earnings forecast. How were Zevra Therapeutics' earnings last quarter? Zevra Therapeutics, Inc. (NASDAQ:ZVRA) issued its quarterly earnings data on Thursday, March, 28th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.20. The firm earned $13.22 million during the quarter, compared to analysts' expectations of $13.35 million. Zevra Therapeutics had a negative trailing twelve-month return on equity of 68.41% and a negative net margin of 167.69%. Who are Zevra Therapeutics' major shareholders? Zevra Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include IFG Advisors LLC (0.04%). Insiders that own company stock include Corey Michael Watton, John B Bode, Joshua Schafer, Matthew R Plooster, R Laduane Clifton, Richard W Pascoe, Tamara A Seymour and Timothy J Sangiovanni. View institutional ownership trends. How do I buy shares of Zevra Therapeutics? Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZVRA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
